CA3118329A1 - Compositions et methodes de prevention et/ou de traitement de la covid-19 - Google Patents
Compositions et methodes de prevention et/ou de traitement de la covid-19 Download PDFInfo
- Publication number
- CA3118329A1 CA3118329A1 CA3118329A CA3118329A CA3118329A1 CA 3118329 A1 CA3118329 A1 CA 3118329A1 CA 3118329 A CA3118329 A CA 3118329A CA 3118329 A CA3118329 A CA 3118329A CA 3118329 A1 CA3118329 A1 CA 3118329A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- acid vaccine
- covid
- subject
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3128078A CA3128078A1 (fr) | 2020-10-09 | 2021-08-09 | Compositions et methodes de prevention et/ou de traitement de la covid-19 |
CA3128660A CA3128660A1 (fr) | 2020-10-09 | 2021-08-19 | Compositions et methodes de prevention et/ou de traitement de la covid-19 |
CA3132188A CA3132188A1 (fr) | 2020-10-09 | 2021-09-28 | Compositions et methodes de prevention et/ou de traitement de la covid-19 |
CN202180083258.0A CN116710129A (zh) | 2020-10-09 | 2021-10-08 | 用于预防和/或治疗covid-19的组合物和方法 |
CA3173429A CA3173429A1 (fr) | 2020-10-09 | 2021-10-08 | Compositions et methodes pour prevenir et/ou traiter la covid-19 |
UY0001039464A UY39464A (es) | 2020-10-09 | 2021-10-08 | Composiciones y métodos para la prevención y/o tratamiento de la covid-19 |
EP21876820.8A EP4225923A1 (fr) | 2020-10-09 | 2021-10-08 | Compositions et méthodes pour prévenir et/ou traiter la covid-19 |
PCT/CA2021/051419 WO2022073131A1 (fr) | 2020-10-09 | 2021-10-08 | Compositions et méthodes pour prévenir et/ou traiter la covid-19 |
TW110137629A TW202222821A (zh) | 2020-10-09 | 2021-10-08 | 用於預防及/或治療covid-19之組合物及方法 |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3,096,009 | 2020-10-09 | ||
CA3096009A CA3096009A1 (fr) | 2020-10-09 | 2020-10-09 | Compositions et methodes de prevention et/ou de traitement de la covid-19 |
CA3,107,232 | 2021-01-26 | ||
CA3107232A CA3107232A1 (fr) | 2020-10-09 | 2021-01-26 | Compositions et methodes de prevention et/ou de traitement de la covid-19 |
CA3113094A CA3113094A1 (fr) | 2020-10-09 | 2021-03-23 | Compositions et methodes de prevention et/ou de traitement de la covid-19 |
CA3,113,094 | 2021-03-23 | ||
CA3116284A CA3116284A1 (fr) | 2020-10-09 | 2021-04-23 | Compositions et methodes de prevention et/ou de traitement de la covid-19 |
CA3,116,284 | 2021-04-23 | ||
CA3,116,932 | 2021-04-30 | ||
CA3116932A CA3116932A1 (fr) | 2020-10-09 | 2021-04-30 | Compositions et methodes de prevention et/ou de traitement de la covid-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3118329A1 true CA3118329A1 (fr) | 2022-04-09 |
Family
ID=81077423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3118329A Pending CA3118329A1 (fr) | 2020-10-09 | 2021-05-12 | Compositions et methodes de prevention et/ou de traitement de la covid-19 |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA3118329A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117919206A (zh) * | 2024-03-22 | 2024-04-26 | 北京大学口腔医学院 | 磁电驱动的磁致伸缩压电纳米颗粒在抗病毒治疗中的应用 |
-
2021
- 2021-05-12 CA CA3118329A patent/CA3118329A1/fr active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117919206A (zh) * | 2024-03-22 | 2024-04-26 | 北京大学口腔医学院 | 磁电驱动的磁致伸缩压电纳米颗粒在抗病毒治疗中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220193223A1 (en) | Nucleic acid vaccines | |
US20190192653A1 (en) | Compositions and methods for tolerizing cellular systems | |
AU2014329452B2 (en) | Polynucleotides encoding low density lipoprotein receptor | |
EP3307305A1 (fr) | Vaccins adaptatifs ciblés | |
WO2016164762A1 (fr) | Polynucléotides codant pour des mutants, au niveau des domaines egf-a et intracellulaire, du récepteur des lipoprotéines basse densité et et leurs procédés d'utilisation | |
AU2014239589A1 (en) | Compositions and methods of altering cholesterol levels | |
CA3128660A1 (fr) | Compositions et methodes de prevention et/ou de traitement de la covid-19 | |
WO2023137550A1 (fr) | Compositions et méthodes pour prévenir et/ou traiter la covid-19 | |
CA3118329A1 (fr) | Compositions et methodes de prevention et/ou de traitement de la covid-19 | |
CA3128078A1 (fr) | Compositions et methodes de prevention et/ou de traitement de la covid-19 | |
CA3116932A1 (fr) | Compositions et methodes de prevention et/ou de traitement de la covid-19 | |
CA3116284A1 (fr) | Compositions et methodes de prevention et/ou de traitement de la covid-19 | |
CA3113094A1 (fr) | Compositions et methodes de prevention et/ou de traitement de la covid-19 | |
CA3146392A1 (fr) | Compositions et methodes de prevention et/ou de traitement de la covid-19 | |
CA3107232A1 (fr) | Compositions et methodes de prevention et/ou de traitement de la covid-19 | |
WO2024073848A1 (fr) | Compositions et méthodes pour prévenir et/ou traiter la covid-19 | |
CA3146411A1 (fr) | Compositions et methodes de prevention et/ou de traitement de la covid-19 | |
CA3154578A1 (fr) | Compositions et methodes de prevention et/ou de traitement de la covid-19 |